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ABSTRACT 
Resting heart rate (RHR) has demonstrated to be an independent risk factor of cardiovascular disease 
and mortality for many years. Recent epidemiological data has emphasized this important, but 
frequently neglected, vital sign as a predictor of mortality in patients diagnosed with cardiac diseases, 
such as coronary heart disease and heart failure, as well as in healthy population. Pathophysiological 
studies illustrate how heart rate is an important contributor to the development and progression of 
cardiovascular diseases. More importantly, clinical trials suggest that the reduction of risk and 
improved outcomes in coronary heart disease and chronic heart failure patients with the use of beta-
blockers and other heart-rate lowering agents, such as ivabradine, is, at least partly, explained by the 
reduction of RHR. Although all this evidence, the measurement of RHR is still overlooked and 
neglected in primary care as an important target for prevention of cardiovascular diseases. Moreover, 
RHR is associated with other traditional cardiovascular risk factors and is an easy way to access which 
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individuals may be in risk and need further investigation or intervention. This evidence highlights the 
importance of RHR and its inclusion in future cardiovascular guidelines should be take into 
consideration. 
 
RESUMO 
A frequência cardíaca em respouso (FCR) demonstrou ser um fator de risco independente de doença 
cardiovascular e mortalidade por vários anos. Dados epidemiológicos recentes enfatizaram este 
importante, mas frequentemente negligenciado, sinal vital como um preditor de mortalidade em 
doentes diagnosticados com patologias cardíacas, tais como doença cardíaca coronária e insuficiência 
cardíaca crónica, e também na população saudável. Estudos patofisiológicos ilustraram a forma como 
a frequência cardíaca é um importante contribuinte para o desenvolvimento e progressão de doenças 
cardiovasculares. Ensaios clínicos sugerem que a redução de risco e melhora no prognóstico dos 
doentes com doença cardíaca coronária ou insuficiência cardíaca crónica com a utilização de beta-
bloqueadores e outros agentes redutores da frequência cardíaca, como a ivabradina, são, pelo menos 
em parte, explicados pela redução da FCR. Apesar de toda esta evidência, a medição da FCR ainda é 
ignorada e neglegenciada nos cuidados de saúde primários como um importante alvo na prevenção de 
doenças cardiovasculares. Além do mais, a FCR está associada a outros fatores de risco tradicionais de 
doença cardiovascular e é uma forma fácil para identificar quais indivíduos poderão estar em risco e 
que precisam de investigação ou intervenção adicional. Esta informação realça a importância da FCR 
e a sua inclusão em futuras diretrizes cardiovasculares deve ser tida em consideração. 
 
INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, 
especially in western countries, accounting for almost a third of all deaths. Coronary heart disease 
(CHD) is the main cause of Years of Life Lost (YLLs) worldwide. Therefore, prevention of CVD is 
one of the main goals of modern medicine.1 
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Heart rate (HR) varies plenty between animal species. Moreover, HR is inversely related to 
average life span in most animals (Figure 1). For example, mammals that have a slower HR are likely 
to have a greater life span that those that have a faster HR.2 
According to World Health Organization (WHO), a risk factor is any attribute, characteristic 
or exposure of an individual that increases the likelihood of developing a disease or injury. Elevated 
HR has long been independently associated with increased risk of CVD and all cause and 
cardiovascular (CV) mortality.3, 4 Additionally, HR is linked to traditional CV risk factors5, 6, as well 
as atherosclerosis7 and levels of inflammatory markers.8 It is also an established prognostic factor in 
CHD and heart failure (HF).9 Resting heart rate (RHR) is acknowledged as a major modifiable factor, 
since its reduction is associated with better outcomes.10 However and unexpectedly, widely known 
indices for CV risk assessment or risk reduction do not include RHR.11 Consequently, most clinicians 
do not value this ease to access vital sign as a risk factor and still don’t consider reduction of RHR as a 
valid preventive measure to promote health.12 
RHR is a simple, accessible and non-invasive cardiovascular parameter and, in the light of all 
recent epidemiologic data and clinical trials, it may be consider a CV risk factor or, at least, be 
recognized, in day-to-day practice, as a predictor of risk. Hence, monitoring and modulation of RHR 
with lifestyle changes and/or medication (such as beta-blockers or ivabradine) may be beneficial for 
cardiovascular health and the prevention of CVD.13 
The aim of this article is to review the existing data associating RHR with CVD and mortality, 
the pathophysiological ways that may explain this association and the current available options to slow 
RHR and how this may be important in cardiovascular protection and global mortality. 
 
METHODS 
This survey was conducted by searching the PubMed database for relevant Portuguese- and 
English-language studies published between January 1, 2003 and December 31, 2017, using the 
following search terms: (("rest"[MeSH Terms] OR "rest"[All Fields] OR "resting"[All Fields]) AND 
("heart rate"[MeSH Terms] OR ("heart"[All Fields] AND "rate"[All Fields]) OR "heart rate"[All 
Fields])) AND (("cardiovascular system"[MeSH Terms] OR ("cardiovascular"[All Fields] AND 
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"system"[All Fields]) OR "cardiovascular system"[All Fields] OR "cardiovascular"[All Fields]) AND 
("risk factors"[MeSH Terms] OR ("risk"[All Fields] AND "factors"[All Fields]) OR "risk factors"[All 
Fields] OR ("risk"[All Fields] AND "factor"[All Fields]) OR "risk factor"[All Fields])). A total of 
1047 matches were found. An initial assessment of eligibility was made through titles and abstracts. 
Potentially relevant articles were retrieved and their full text were reviewed independently by the 
authors for final decision on inclusion. Unavailable and irrelevant articles were excluded. Additional 
relevant papers found in the reference lists of the articles retrieved from the initial selection were also 
included. A total of 78 articles made up the final study. 
 
HEART RATE – PATHOPHYSIOLOGIC MECHANISMS  
In order to explain the association between RHR and CV events, we need to understand the 
effects of an elevated RHR in the human body (Figure 2). These damaging effects contribute to the 
pathogenesis of CV disease.10 
 
Myocardial ischemia 
 The cause of myocardial ischemia is an imbalance between oxygen demand and supply. A fast 
RHR leads to an increase in ventricular work, and, therefore, enhanced myocardial oxygen 
consumption. Coronary blood flow occurs mostly during diastole. With increasing heart rate, diastole 
(when coronary perfusion is performed) shortens proportionally more than systole does. Hence, 
coronary perfusion and myocardial oxygen supply diminish, which is not enough to suffice the heart’s 
needs, especially when there are atherosclerotic obstructions.14 Contrariwise, reduction of RHR 
enhances and redistributes myocardial blood flow. Recently, Dillinger et al. 15 demonstrated, for the 
first time in humans, a significant improvement in myocardial perfusion in patients treated with 
ivabradine when compared with placebo, with a 39% absolute increase in Buckberg index, which is 
related to better myocardial supply/demand ratio. This was mainly due to a significant lengthening of 
diastolic time, without a comparable increase in ejection time. 
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Atherosclerosis 
 Experimental and clinical evidence suggests that chronic elevated RHR itself contributes to 
the pathogenesis of atherosclerosis, probably affecting its initiation and course, as well as the severity 
of the disease.14 Also, increased RHR facilitates plaque disruption and progression of coronary 
atherosclerosis, that may influence the clinical outcomes in patients with coronary heart disease.16 
Endothelial dysfunction is considered a key event in the development of atherosclerosis and is 
a common consequence of different CV risk factors. In animal models, elevated RHR is associated 
with endothelial dysfunction, vascular oxidative stress and atherogenesis.16-18 For a long time, there 
has been evidence that an accelerated RHR is associated with lipid-induced atherogenesis in animals. 
In fact, Kaplan et al. 16 showed association between naturally occurring differences in RHR and 
coronary atherosclerosis in monkeys. These animals with high RHR had atherosclerotic lesions more 
than twice as extensive as those with low RHR, independently of the lipid profile. More recently, two 
studies aimed to demonstrate a link between RHR and endothelial function. Custodis et al. 17 studied 
cholesterol-fed apolipoprotein (Apo)E-/- mice, a disease model for endothelial dysfunction, treated 
with ivabradine. Ivabradine treated mice showed improvement in endothelium-dependent vasodilation 
and a significant decrease in vascular oxidative stress, in the absence of blood pressure (BP) changes 
or lipid lowering. Furthermore, there was a significant reduction in atherosclerotic plaque size in the 
aortic root and ascending aorta, despite severe hypercholesterolemia. Drouin et al. 18 also 
demonstrated that, in dyslipidemic mice expressing the human ApoB-100, RHR reduction with 
ivabradine, but not metoprolol, prevented the decline of the endothelial vasodilator function of renal 
and cerebral arteries and limited the cardiac dysfunction, more specifically, improving diastolic 
function in dyslipidemic mice.  
For human studies, there has been also recent data regarding RHR and subclinical 
atherosclerosis. Firstly, Rubin et al. 19 demonstrated a link between elevated RHR and atherosclerosis, 
as assessed by the incidence and progression of coronary artery calcium (CAC), in a healthy 
population. After adjustment for CV risk factors, participants with a baseline RHR > 80 beats per 
minute (bpm) had an increased risk of incident CAC when compared with a resting heart rate < 60 
bpm. Among the group with CAC present at baseline, participants whose RHR > 80 bpm had a greater 
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CAC score progression than those whose RHR < 60 bpm. Similarly, Han et al. 20 found an association 
between high RHR and subclinical atherosclerosis, as measured by CAC scoring. After adjustment, 
each 10 bpm increase in RHR was associated with higher odds of a CAC score above 100 (odds ratio 
(OR) = 1.13) or 400  (OR = 1.22) and, in particular, RHR≥80 bpm was associated with an OR of 1,42 
for having a CAC>100 and an OR of 1,86 for having a CAC>400. Last, but not least, Wang et al. 7, 
using ultrasound measurements of carotid intima-media thickness (c-IMT) and carotid plaque, 
demonstrated that elevated RHR is associated with carotid atherosclerosis in asymptomatic population 
without known CVD. Participants with RHR > 81 bpm had an OR of 2.82 for elevated c-IMT, and an 
OR of 2.00 for carotid plaque, compared to participants with RHR < 67 bmp. These associations were 
independent of conventional CV risk factors. Taken together, these studies suggest that atherosclerosis 
may be a potential mediator between RHR and adverse CV outcomes. However, although these 
experimental studies describe the pathophysiology underlying the CV effects of RHR, it is still 
unknown the molecular mechanism behind it and should require further investigation.14 
 
Arterial stiffness 
 Blood vessels adapt to mechanical forces and undergo continuous remodelling, changing their 
geometry, structure and elastic properties. Compliance of the vessels reduces gradually with vascular 
ageing. This reduction of compliance is also known as arterial stiffness, and it’s a mark of adverse 
structural and functional changes within the vessel wall that can be early detected.14 Arterial stiffness 
itself is associated with CAC, predicts severity of atherosclerosis 19 and is related with adverse CV 
events.14 
 In animal models, increased RHR is related with a progressive and markedly reduced arterial 
compliance and distensibility.11, 14 Similarly, RHR is strongly associated with arterial stiffness in 
asymptomatic patients, after adjustment for potential confounders.21, 22 Park et al. 21 aimed to 
determine the association between RHR and arterial stiffness measured by brachial-ankle pulse wave 
velocity (baPWV) in healthy adults. He observed that age-adjusted baPWV mean values increased 
gradually with RHR elevation. The OR for high baPWVs in the highest RHR quartile was 3.66, after 
adjusting for several confounding factors, including the presence of drugs that could modify both RHR 
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and baPWV, such as antihypertensive drugs, antidiabetic drugs, and lipid-lowering drugs. Likewise, 
Whelton et al. 22 investigated the relationship between RHR and arterial stiffness of the carotid and the 
aorta (a peripheral and a central arteries, respectively) in an asymptomatic population, using 
imagiology methods. Carotid and aortic distensibility decreased gradually with increasing RHR (p < 
0.001 and 0.009, respectively). This association persisted after adjustment for traditional CV risk 
factors and, also, AV nodal blocker medication use. It’s important to refer that this relationship was 
stronger and more statistically significant for carotid artery distensibility than aorta. 
 
Prothrombotic state 
Thrombosis has an important role in plaque development and acute coronary syndromes. With 
that in mind, Tofler et al. 6, using the Framingham Offspring study data, showed that higher RHRs are 
associated with a prothrombotic state, in both men and women. On age-adjusted analysis, significant 
associations were found between RHR and fibrinogen, plasma viscosity, plasminogen activator 
inhibitor antigen (PAI-1), tissue plasminogen activator (tPA) antigen, and factor VII antigen. After 
adjustment for other CV risk factors, fibrinolytic measurements and plasma viscosity persisted 
strongly associated with RHR in both sexes but only women showed a significant adjusted association 
for fibrinogen and factor VII, while men showed a significant association for von Willebrand factor 
(vWf).  
 
Inflammatory state 
Elevated plasma levels of inflammatory markers (e.g. C-reactive protein (CRP)) are associated 
with endothelial dysfunction and future CV risk.14 There’s clinical evidence about increased RHR 
being linked to a pro-inflammatory state and, thus, may contribute to endothelial dysfunction and, 
also, promote atherosclerosis by up-regulation of inflammatory cytokines.8, 23-25 Rogowski et al. 23 
proposed an association between a single RHR measurement and the presence of a microinflammatory 
response in a group of apparently healthy individuals and in those with atherothrombotic risk factors. 
There was a gradual increase of inflammatory biomarkers with RHR increment. A significant age- and 
body mass index-adjusted Pearson’s partial correlation was reported between RHR and the 
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concentration of fibrinogen (r = 0.190, p<0.001), absolute polymorphonuclear count (r = 0.177, 
p<0.001) and also CRP (r = 0.171, p<0.001). After excluding all individuals taking any medication 
with potential influence on RHR or on inflammatory biomarkers, as well as smoking patients and 
patients with anemia, the correlation remained strong.  
 Three prospective studies also reported relationship between RHR and inflammatory response, 
but went further and tried to find a link of these two factors with incident CV outcomes.8, 24, 25 
Although RHR is associated with mortality as well as markers of chronic low-grade inflammation, 
when adjusting for these markers, Jensen et al. 24 found that RHR is an independent risk factor for CV 
and all-cause mortality, and not merely a marker of chronic inflammation. Similarly, Nanchen et al. 25 
seeked to assess the association between RHR and incident HF and CV mortality, and whether these 
associations are due to systemic inflammation and endothelial dysfunction. CRP, IL-6, tPA, and vWf 
levels were all positively correlated with RHR and remained independently associated after 
multivariate analyses. Plus, RHR was associated with HF hospitalization (hazard ratio (HZR) = 1.78) 
and CV mortality (HZR = 1.74) after adjustment for multiple factors but was only partially explained 
by inflammatory and endothelial dysfunction markers. Lastly, Hartaigh et al. 8 proposed a strong 
interaction between RHR and inflammation in CV mortality. Their study followed prospectively 3267 
patients, scheduled for coronary angiography, and measured RHR and five inflammatory markers (IL-
6, CRP, serum amyloid A, neutrophils, and fibrinogen). Elevated levels of inflammatory markers were 
associated with CV mortality, however, this risk was amplified four-folds in patients with a high RHR 
(≥75 bpm), when compared with those with RHR lower than 75 bpm (HZR 7.50 versus 1.84). 
Furthermore, the HZRs remained unaltered after adjusting for multiple risk factors. Contrariwise to the 
two previous cited articles, this study suggests that may be a strong synergistic power of inflammatory 
activity and persistent elevated RHR for CV mortality.8  
 
Autonomic dysfunction 
 The sinoatrial node activity determines HR, and it’s mainly influenced by the sympathetic and 
parasympathetic nervous systems. More specifically, RHR is under tonic inhibitory control by the 
vagus nerve. An autonomic imbalance, meaning a sympathetic overactivity or a diminished 
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parasympathetic activity (or both), may be one of the main underlying causes of an elevated RHR and, 
consequently, of CV poor outcomes.10 As Thayer et al. 26 reviewed, a decreased vagal function is 
associated with an increased risk for CV disease and mortality, and these effects are independent of 
traditional risk factors. RHR, heart rate variability (HRV) and heart rate recovery (HRR) are all strong 
indicators of cardiac autonomic function and, as a result, can be used to assess autonomic imbalance. 
In brief, an elevated RHR, a reduced HRV and a slow HRR after exercise are all associated with a 
reduced vagal function as well as increased risk in CV morbidity and mortality.  
 Recently, Wulsin et al. 27 investigated, in the FHS Offspring Cohort, whether autonomic 
imbalance, measured by RHR and HRV, was an independent predictor of each of the five components 
of metabolic syndrome (hyperglycemia, high BP, high triglycerides, low HDL, and high body mass 
index (BMI)) as well as the development of CVD, diabetes, and early mortality. They found a strong 
and significant association between high RHR and small HRV and the development of hyperglycemia 
and high BP within 12 years, but this association was not statistically as strong for the other 3 
metabolic factors. However, small HRV predicted the development of CVD and diabetes, as well as 
early death for males, whereas higher RHR predicted CVD for the younger, incident diabetes, and 
early death.  
 
HEART RATE - EPIDEMIOLOGICAL DATA 
Increased RHR has surfaced as an independent risk factor both in primary care and in patients 
with hypertension, CHD and chronic HF. Epidemiological studies support a strong association 
between RHR and negative CV outcomes.14 
 
Mortality in general population 
Several epidemiological studies demonstrated that an increase in RHR is an independent 
predictor of CV and overall mortality in the general population.3, 28-30 
 Cooney et al. 29 followed a group of apparently healthy men and women, excluding those with 
preexisting CHD, angina, HF, or on antihypertensive therapy. When comparing RHR >90 bpm with 
<60 bpm, there was an almost 2-fold increased risk of CV mortality in men and 3-fold increased risk 
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in women. This association was independent and similar in magnitude to the risk associated with 
current smoking. Besides, RHR, as a continuous variable, remained a significant predictor of CV 
mortality after full adjustment (HZR = 1.24 for men and HZR = 1.32 for women). Soon after, 
Johansen et al. 30 aimed to test which of 3 measures of HR (RHR, 24h average HR and night-time HR) 
had the strongest prognostic value for CV morbidity and mortality in a population with no apparent 
heart disease. They concluded that all measures of increased HR are associated with increased 
mortality and CV risk in middle-aged and elderly apparently healthy subjects. However, night-time 
HR had the strongest prognostic value after multivariable analysis. 
A recent meta-analysis study by Zhang et al. 3 aimed to assess the risk of all-cause and CV 
mortality associated with each increment of 10 bpm, the possible dose-response relation and the effect 
of traditional risk factors of CV disease on the association of RHR with risk of all-cause and CV 
mortality, by analysing prospective cohort studies involving the general population. According to this 
study, the risk of all-cause and CV mortality increased by 9% and 8%, respectively, for every 10 bpm 
increment of RHR. Also, when compared with 45 bpm, the risk of all-cause mortality increased 
significantly with increasing RHR in a linear relation, but the risk of CV mortality increased 
significantly at 90 bpm. Besides, using 70 bpm as reference, the linear dose-response analysis 
indicated a protective effect of lower RHR. Lastly, since higher RHR coexist with traditional risk 
factors of CV disease, Zhang et al. concluded that the association of RHR with risk of all-cause and 
CV mortality is independent of traditional CV factors, suggesting that RHR is a strong and 
independent predictor of mortality in the general population. 
 
Incidence of cardiovascular disease – role of RHR  
Epidemiological data suggests that higher levels of RHR are associated with incident CVD, 
such as HF, stable CHD, acute myocardial infarction (MI) and stroke. 
More specifically, several studies confirmed the relationship between RHR and incidence of 
HF. In one of these, the Rotterdam study 31, RHR was measured in a group of healthy adults without 
pre-existing heart disease or HR modifying medication use. Both single and repeated measurements of 
RHR identified men at higher risk of developing HF, independently of other CV risk factors, including 
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CHD. In women, this association could not be demonstrated. In other study, Opdahl et al. 32 
hypothesized that RHR could be related with HF independently of hypertension, diabetes and CHD, 
and that an increased RHR might be an early marker of left ventricular (LV) dysfunction that precedes 
traditional indexes of LV dysfunction and clinical disease. In this large multi-ethnic cohort without 
symptoms of CVD at inclusion, increased RHR was strongly associated with the development LV 
dysfunction, as well as incident HF. Adjusted analyses of RHR as a continuous variable demonstrated 
that for every increase of 1 bpm, there was a 4% greater risk for incident HF. When compared with a 
RHR of 55 bpm, higher RHRs were associated with greater relative risks for incident HF. These 
findings were independent of demographic confounders, established CV risk factors, and markers of 
subclinical atherosclerosis, as well as LV structure and function at inclusion. When excluding 
participants with incident CHD events, RHR remained an important predictor for incident HF, as well 
as for declining LV function. In brief, RHR was related to incident HF and it’s an important predictor 
of progressive subclinical LV dysfunction.  
In 3 cohorts of middle-aged to older individuals without HF at baseline, Khan et al. 33 
observed, in contrast to previous studies, a non-linear J-shaped association between RHR and risk of 
incident HF, meaning that there’s an increased risk of HF at both low and high levels of RHR, 
independently of conventional HF risk factors. Lastly, a study by Pfister et al. 34 showed similar 
results, although they restricted the analysis to the normal range (from 50 bpm to 100 bpm), because, 
according to them, levels below or above this range may be the result of latent arrhythmic or structural 
cardiac disease. 
When considering incident CHD in a healthy population, it’s more controversial to confirm a 
relation with RHR. For example, after controlling for potential confounders, RHR is independently 
associated with the risk of MI and all-cause death in the general population.35 However, one study 
showed a positive and continuous association between RHR and mortality but not coronary events.36 
In fact, when comparing RHR below and above 70 bpm, individuals with RHR ≥ 70 bpm had 50% 
increased hazard ratios of events (HZR = 1.53). For coronary events, there were also increased hazard 
ratios with RHR ≥ 70 bpm, but they weren’t statistically significant (p = 0.68).  
Two recent studies by Sharashova et al. also display contrasting results, whether they use a 
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single measurement of RHR 13 or identify long-term RHR trajectories by measuring RHR in three 
separate occasions, which reflected individual RHR change over a 15-year survey period.37 In the first 
study 13, in both men and women, the risk of incident MI and total death increased gradually with 
increasing RHR. In the second study 37, increasing and elevated RHR trajectories were associated with 
an increased risk of MI and total death in men, but not in women. The latter study suggested that the 
changes in RHR address additional information, such as control of autonomic activity.  
A recent meta-analyses by Zhang et al. 4, that included 45 nonrandomized prospective cohort 
studies, reported that, when concerning general population, RHR is an independent predictor of CHD 
and stroke but not sudden death. 
 
Association of RHR with other cardiovascular risk factors 
RHR is in close relationship with traditional CV risk factors. For example, there’s a strong 
association between RHR and the presence of metabolic syndrome in both men and women. In fact, 
even a small increase in RHR has a clear influence on the odds of having metabolic syndrome.38 
Besides higher RHR being an independent risk factor for existing metabolic syndrome, it is also a risk 
factor for its incidence in those without it at baseline.5 The relationship between RHR and metabolic 
syndrome arises probably due to a mechanism by which RHR increases the risk of CV and all-cause 
mortality.  
Kizilbash et al. 39 investigated the association of lower RHR with lower levels of CV risk 
factors among individuals with normal BMI without any history of CVD. A lower RHR was 
associated with lower mean BP and cigarette use in both men and women, and with lower mean total 
cholesterol and prevalence of diabetes in men but not women. 
Subjects with history of smoking, irrespective of prior or current tobacco consumption, have 
greater relative risk of elevated RHR compared to never smokers.40 Additionally, a large mendelian 
randomization meta-analysis by Linneberg et al. 41 supports that smoking is causally associated with 
higher levels of RHR, but not with variations in BP neither with risk of hypertension. These findings 
suggest that part of the CV risk of smoking may occur via increasing RHR. 
 More than 70 years ago, a study by Levy et al. 42 demonstrated that RHR had equivalent 
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prognostic power to high BP for the development of hypertension. In fact, home-measured RHR is a 
strong predictor of CVD and mortality in the general population, independently of home-measured BP 
value and even in normotensive individuals. Moreover, RHR and BP have a synergic power in 
predicting the risk of CVD.43 Several studies have demonstrated that RHR is significantly associated 
with developing hypertension in normotensive population and that the increased risk of hypertension 
was evident at RHR levels not considered to be tachycardia.44-46 
Apart from being associated with the risk of developing hypertension, RHR also has 
prognostic importance in already hypertensive patients. In patients with mild to severe hypertension, 
RHR was an independent predictor of all-cause and CV mortality.47 In this study, Paul et al. 47 also 
showed that the change in RHR achieved during follow-up of these patients was a better predictor of 
risk than baseline or final RHR. When testing for HF outcome, Okin et al. 48 found similar results. 
During treatment of hypertension, higher in-treatment RHR is independently associated with increased 
risk of developing new-onset HF. In fact, for every 10 bpm increase, there was a 45% greater risk of 
new-onset HF. In contrast, the baseline RHR was a much less powerful predictor of incident HF. 
Saxena et al. 49 aimed to study the protective role of lower RHR on CV and overall mortality. When 
they stratified the data by hypertension, hypertensive individuals with high RHR (≥80 bpm) were at a 
1.38 and 1.52 times greater risk for all-cause and CV mortality, respectively, when compared to those 
with hypertension and lower RHRs (<60 bpm). In patients with resistant hypertension, Modolo et al. 50 
showed that elevated RHR was one of the independent predictors of silent myocardial ischemia (OR = 
1.23) along with diabetes, microalbuminuria, endothelial dysfunction and LV mass. Finally, Ryu et 
al.51 showed that individuals with elevated RHR and hypertension simultaneously, have a greater risk 
for all-cause and CV mortality, compared to those with elevated RHR or hypertension alone. All these 
findings suggest that elevated RHR should not be regarded as a much less serious risk factor than 
hypertension per se, and that frequently they go hand in hand. 
 
Outcomes in patients with cardiovascular disease 
Once the cardiac disease is established, RHR is considered an important prognostic factor in 
such patients, so much so that reducing RHR is a main therapeutic target in these conditions. The 
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prognostic value of RHR has been demonstrated extensively in multiple recent studies in patients with 
stable CHD 52-56, acute MI 57, 58 and HF 59-63.  
 
REDUCTION OF HEART RATE 
As we observed so far, RHR is partly responsible for the pathogenesis of CVD, is an 
independent predictor of CV and overall mortality and has strong prognostic value in CV conditions. 
Thus, it is clear that reducing RHR is a therapeutic target and has implications in the evolution of 
patients with CVD.64 Nevertheless, reduction of RHR is not part of primary prevention 
recommendations and guidelines for the healthy population that have this simple vital sign 
consistently elevated.65 Fortunately, there are non-pharmacologic ways to reduce RHR in long term, 
such as exercise 66, that have beneficial effects in the prevention of CVD.49   
 
Why? 
In the general population and in patients with CVD, those who have lower (but not too low) 
RHR have better outcomes.3, 4 In various studies, treatments to lower RHR have demonstrated better 
outcomes, being reducing overall and CV mortality and hospitalizations, especially in patients with 
CHD and HF.64, 67, 68 This data suggests HR reduction is probably the main mechanism behind the 
prognostic benefit of beta-blockers and ivabradine in CHD and HF, and that’s one of the reasons they 
are recommended in the management of these patients.69  
 
How?  
Pharmacologic treatment 
Beta-blockers have been used for many years for their anti-ischemic, anti-arrhythmic and anti-
hypertensive properties, and, more recently, they have become more important in the management of 
HF patients.64 Although it has numerous benefits, beta-blockage as a HR-lowering therapy has some 
limitations. Firstly, beta-blockers have effects on the CV system outside reducing RHR, for example 
negative inotropic effect 10 and enhanced pulse-wave reflection.69 Secondly, beta-blockers are 
generally well tolerated, but side-effects may occur, which limits its use in certain patients.64 
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Furthermore, RHR is poorly controlled in many patients with CHD 70 and HF 64, as those patients 
maintain a RHR above 70 bpm despite optimal beta-blockage therapy. On top of this evidence, 
reduction of RHR with some of beta-blocker drugs in hypertensive patients can increase the risk of 
CV events and death.71  
Contrastingly to beta-blockers, selective If-inhibitors, such as ivabradine, reduce RHR without 
altering cardiac contractility or atrioventricular conduction. Since its development, ivabradine allowed 
to explore and investigate whether reducing RHR per se is associated with improved outcome. 9 In the 
BEAUTIFUL Trial 67 was demonstrated that selective RHR decrease by ivabradine was beneficial to 
reduce major CV events (hospitalization due to MI and coronary revascularization) in patients with 
stable CHD and LV systolic dysfunction with limiting angina, especially in patients with a baseline 
RHR above 70 bpm. Soon after, the SHIFT trial 68 showed that selective RHR reduction by ivabradine 
was associated a significant reduction of poor CV outcomes in patients with HF, although CV and all-
cause mortality were not significantly reduced by ivabradine. The beneficial effect was consistent 
across all subgroups. Although ivabradine is safe and well tolerated, it can cause excessive 
bradycardia68, 72, although does not appear to impact outcomes.72 Another disadvantage of ivabradine 
is, since it acts in the sinoatrial node, it can only be use in patients with sinus rhythm.64 
 
Physical activity 
It is known that elevated RHR is associated with a poor cardiorespiratory fitness (CRF).11 
Indeed, RHR is lower in individuals who practice vigorous leisure activity or participate in sports, and 
is higher in sedentary subjects.11, 73-75 Because of this evidence, RHR is often used to estimate CRF, 
and, this is, possibly, the link to CV outcomes.76 Although RHR and CRF can be related, they can both 
independently predict mortality. In fact, several studies demonstrated that RHR is significantly related 
with mortality, irrespective of CRF 49 or physical activity (PA).77 However, PA, especially aerobic 
exercise, can be a simple non-pharmacologic approach for reducing RHR. According to Rangul et 
al.75, individuals that maintain high PA from adolescence to young adulthood have better CV risk 
profile, including lower RHR, than inactive individuals. This suggests that interventions on PA should 
start early in life in order to confer a beneficial CV risk profile. In older population, 12 months of 
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aerobic PA does not confer a significant reduction on RHR 78, and the authors suggest that aerobic PA 
lasting longer than 12 months may be more effective for slowing RHR in older people. In a study by 
Delecluse et al.74, a fitness program consisting of 20 weeks endurance training combined with 
resistance training is equally effective in lowering RHR and CV risk profile as endurance training 
alone in older population. This indicates that to obtain health benefits in an untrained older male 
population, the engagement in fitness training for 20 weeks is more important that the specific 
exercise mode or intensity. 
 
CONCLUSION 
A large body of evidence supports RHR as a strong and independent risk factor for global 
mortality, including CV mortality. This applies for diverse populations, such as healthy subjects and 
the ones in risk of CV disease, as well as patients diagnosed with heart diseases, like CHD and HF. 
Experimental evidence validates the role of elevated RHR in myocardial ischemia, endothelial 
dysfunction and atherosclerosis, as well as in other pathophysiological mechanisms, that may explain 
the modus operandi of RHR in the development of poor CV outcomes. 
The association of RHR with risk does not provide unequivocal evidence of causation. 
However, the persistence of this association, after controlling for other potentially confounding 
variables, suggests that RHR is an independent risk factor and not merely a risk indicator. Moreover, 
in most studies, the risk clearly increases at heart rates far below the common definition of 
tachycardia. Still, RHR is rarely taken into account in the assessment of CV risk despite being a 
simple and accessible vital sign.  
Although in HF and CHD, RHR is an important therapeutic target, in subjects without CV 
disease the efficacy and cost-effectiveness of HR reduction treatment and the optimal RHR has yet to 
be determined. However, a healthy lifestyle coupled with the practice of physical activity since youth 
can reduce RHR in the long run and is associated with better CV outcomes and an improved quality of 
life. 
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FIGURE 1: Semilogarithmic relation between HR and life expectancy in 15 mammal species.  HR is 
inversely related with life expectancy in all species, except humans (that live longer, presumably 
related to the intervention of medical care). Adapted from Levine 2 with permission of the publisher. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2: The role of elevated rhr in the pathogenesis of cardiovascular diseases and increased 
cardiovascular risk 
	 18	
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www.nlm.nihgov/mesh/meshhome.html.
O resumo e as palavras-chave em inglês devem ser apresentados 
da mesma forma.
Texto
Deverá conter as seguintes partes devidamente assinaladas: a) In-
trodução; b) Métodos; c) Resultados; d) Discussão e e) Conclusões. 
Poderá utilizar subdivisões adequadamente para organizar cada uma 
das secções.
As abreviaturas das unidades de medida são as recomendadas pela 
RPC (ver Anexo II).
Os agradecimentos situam-se no final do texto.
Bibliografia
As referências bibliográficas deverão ser citadas por ordem numérica 
no formato ‘superscript’, de acordo com a ordem de entrada no texto.
As referências bibliográficas não incluem comunicações pessoais, 
manuscritos ou qualquer dado não publicado. Todavia podem estar 
incluídos, entre parêntesis, ao longo do texto.
São citados abstracts com menos de dois anos de publicação, 
identificando-os com [abstract] colocado depois do título.
As revistas médicas são referenciadas com as abreviaturas utiliza-
das pelo Index Medicus: List of Journals Indexed, tal como se publi-
cam no número de Janeiro de cada ano. Disponível em:   http://www.
ncbi.nlm.nih.gov/entrez/citmatch_help.html#JournalLists.
O estilo e a pontuação das referências deverão seguir o modelo 
Vancouver 3.
Revista médica: Lista de todos os autores. Se o número de autores 
for superior a três, incluem-se os três primeiros, seguidos da abreviatu-
ra latina et al. Exemplo:
 17. Sousa PJ, Gonçalves PA, Marques H et al. Radiação na AngioTC 
cardíaca; preditores de maior dose utilizada e sua redução ao lon-
go do tempo. Rev Port cardiol, 2010; 29:1655-65
Capítulo em livro: Autores, título do capítulo, editores, título do 
livro, cidade, editora e páginas. Exemplo:
 23. Nabel EG, Nabel GJ. Gene therapy for cardiovascular disease. 
En: Haber E, editor. Molecular cardiovascular medicine. New York: 
Scientific American 1995. P79-96.
Livro: Cite as páginas específicas. Exemplo:
 30. Cohn PF. Silent myocardial ischemia and infarction. 3rd ed. New 
York: Mansel Dekker; 1993. P. 33.
Material electrónico: Artigo de revista em formato electrónico. 
Exemplo:
 Abood S. Quality improvement initiative in nursing homes: the 
ANA acts it an advisory role. Am J Nurs. [serie na internet.] 2002 
Jun citado 12 Ago 2002:102(6): [aprox. 3] p. Disponível em: http://
www.nursingworld.org/AJN/2002/june/Wawatch.htm
. A Bibliografia será enviada como texto regular, nunca como nota de 
rodapé. Não se aceitam códigos específicos dos programas de gestão 
bibliográfica.
1. Figuras
As figuras correspondentes a gráficos e desenhos são enviadas no 
formato TIFF ou JPEG de preferência, com uma resolução nunca 
inferior a 300 dpi e utilizando o negro para linhas e texto. São 
alvo de numeração árabe de acordo com a ordem de entrada no 
texto.
• A grafia, símbolos, letras, etc, deverão ser enviados num tamanho que, 
ao ser reduzido, os mantenha claramente legíveis. Os detalhes especiais 
deverão ser assinalados com setas contrastantes com a figura.
• As legendas das figuras devem ser incluídas numa folha aparte. No final 
devem ser identificadas as abreviaturas empregues por ordem alfabética.
• As figuras não podem incluir dados que dêem a conhecer a pro-
veniência do trabalho ou a identidade do paciente. As fotografias das 
pessoas devem ser feitas de maneira que estas não sejam identifica-
das ou incluir-se-á o consentimento por parte da pessoa fotografada.
Tabelas
São identificadas com numeração árabe de acordo com a ordem de 
entrada no texto.
Cada tabela será escrita a espaço duplo numa folha aparte.
• Incluem um título na parte superior e na parte inferior são refe-
ridas as abreviaturas por ordem alfabética.
• O seu conteúdo é auto-explicativo e os dados que incluem não 
figuram no texto nem nas figuras.
2. Artigos de Revisão
Nº máximo de palavras do artigo sem contar com o resumo e qua-
dros- 5.000
Nº máximo de palavras do Resumo - 250
Nº máximo de Figuras - 10
Nº máximo de quadros - 10
Nº máximo de ref. bibliográficas - 100
3. Cartas ao Editor
Devem ser enviadas sob esta rubrica e referem-se a artigos publica-
dos na Revista. Serão somente consideradas as cartas recebidas no 
prazo de oito semanas após a publicação do artigo em questão.
• Com espaço duplo, com margens de 2,5 cm.
• O título (em português e em inglês), os autores (máximo quatro), 
proveniência, endereço e figuras devem ser especificados de acordo 
com as normas anteriormente referidas para os artigos originais.
• Não podem exceder as 800 palavras.
• Podem incluir um número máximo de duas figuras. As tabelas 
estão excluídas.
4. Casos Clínicos
Devem ser enviados sob esta rubrica.
• A espaço duplo com margens de 2,5 cm.
• O título (em português e em inglês) não deve exceder 10 palavras
Os autores (máximo oito) proveniência, endereço e figuras serão 
especificados de acordo com as normas anteriormente referidas para 
os artigos originais.
O texto explicativo não pode exceder 3.000 palavras e contem in-
formação de maior relevância. Todos os símbolos que possam constar 
nas imagens serão adequadamente explicados no texto.
Contêm um número máximo de 4 figuras e pode ser enviado mate-
rial suplementar, como por exemplo vídeoclips.
5. Imagens em Cardiologia
• A espaço duplo com margens de 2,5 cm.
• O título (em português e em inglês) não deve exceder oito palavras
• Os autores (máximo seis), proveniência, endereço e figuras serão 
especificados de acordo com as normas anteriormente referidas pa-
ra os artigos originais.
• O texto explicativo não pode exceder as 250 palavras e contem 
informação de maior relevância, sem referências bibliográficas. To-
dos os símbolos que possam constar nas imagens serão adequada-
mente explicados no texto.
• Contêm um número máximo de quatro figuras.
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ANEXO II
Símbolos, abreviaturas de medidas ou estatística
6. Material adicional na WEB
A Revista Portuguesa de Cardiologia aceita o envio de material 
electrónico adicional para apoiar e melhorar a apresentação da sua 
investigação científica. Contudo, unicamente se considerará para 
publicação o material electrónico adicional directamente relaciona-
do com o conteúdo do artigo e a sua aceitação final dependerá do 
critério do Editor. O material adicional aceite não será traduzido e 
publicar-se-á electronicamente no formato da sua recepção.
Para assegurar que o material tenha o formato apropriado reco-
mendamos o seguinte:
  Formato Extensão Detalhes
Texto Word .doc ou docx Tamanho máximo 300 Kb
Imagem TIFF .tif Tamanho máximo 10MB
Audio MP3 .mp3 Tamanho máximo 10MB
Vídeo WMV .wmv Tamanho máximo 30MB
Os autores deverão submeter o material no formato electró-
nico através do EES como arquivo multimédia juntamente com 
o artigo e conceber um título conciso e descritivo para cada 
arquivo.
Do mesmo modo, este tipo de material deverá cumprir também 
todos os requisitos e responsabilidades éticas gerais descritas nes-
sas normas.
O Corpo Redactorial reserva-se o direito de recusar o material 
electrónico que não julgue apropriado.
ANEXO I
DECLARAÇÃO
Declaro que autorizo a publicação do manuscrito:
Ref.ª ........................................................................................
Título  ...........................................................................................
.........................................................................................................
........................................................................................................
do qual sou autor ou c/autor.
Declaro ainda que presente manuscrito é original, não foi 
objecto de qualquer outro tipo de publicação e cedo a inteira 
propriedade à Revista Portuguesa de Cardiologia, ficando a 
sua reprodução, no todo ou em parte, dependente de prévia 
autorização dos editores.
Nome dos autores: 
.........................................................................................................
.........................................................................................................
Assinaturas: 
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Designação
Ampere
Ano
Centímetro quadrado
Contagens por minuto
Contagens por segundo
Curie
Electrocardiograma
Equivalente
Grau Celsius
Grama
Hemoglobina
Hertz
Hora
Joule
Litro
Metro
Minuto
Molar
Mole
Normal (concentração)
Ohm
Osmol
Peso
Pressão parcial de CO2
Pressão parcial de O2
Quilograma
Segundo
Semana
Sistema nervoso central
Unidade Internacional
Volt
Milivolt
Volume
Watts
Estatística:
Coeficiente de correlação
Desvio padrão (standard)
Erro padrão (standard) da média
Graus de liberdade
Média
Não significativa
Número de observações
Probabilidade
Teste «t» de Student
Português
A
ano
cm2
cpm
cps
Ci
ECG
Eq
°C
g
Hb
Hz
h
J
L ou L
m
min
M
mol
N
Ω
osmol
peso
pCO2
pO2
kg
s
Sem
SNC
UI
V
mV
Vol
W
r
DP
EPM
gl
χ
NS
n
p
teste t
Inglês
A
yr
cm2
cpm
cps
Ci
ECG
Eq
°C
g
Hb
Hz
h
J
I ou L
m
min
M
mol
N
Ω
osmol
WT
pCO2
pO2
kg
sec
Wk
CNS
IU
V
mV
Vol
W
r
SD
SEM
df
χ
NS
n
p
t test
